U.S. FDA seeks new warnings on drugs from Pfizer, Lilly and AbbVie
JAK inhibitors block inflammation-causing enzymes, known as Janus kinases, and target autoimmune diseases such as rheumatoid arthritis and ulcerative colitis.
The FDA said the Lilly drug Olumiant and AbbVie’s Rinvoq have similar operating mechanisms, leading to the possibility of risks seen in the Xeljanz safety trial.
Incyte Corp’s Jakafi and Bristol Myers Squibb’s JAK inhibitor Inrebic will not need warnings as they are not approved to treat inflammatory conditions, the agency said. ■